期刊文献+

朗格汉斯组织细胞增多症111例预后分析 被引量:2

Prognostic analysis of 111 cases analysis Langerhans cell histiocytosis
原文传递
导出
摘要 目的探讨朗格汉斯组织细胞增生症患者的预后情况及影响预后的因素。方法回顾性分析1996年9月至2014年5月郑州大学附属肿瘤医院收治的111例朗格汉斯组织细胞增多症患者的临床和随访资料,分析患者的复发情况,对可能影响患者无事件生存时间(EFS)和总生存时间(OS)的因素进行单因素分析。结果多部位骨质受累和多系统受累患者的复发率分别高于非多部位骨质受累和单系统受累的患者(P<0.05)。单因素分析显示,发病年龄≤2岁、多部位骨质受累、多系统受累、有危险器官受累、初始治疗无效的患者无事件生存率和总生存率均显著降低,应用化疗患者的无事件生存率和总生存率均显著升高(P<0.05)。结论发病年龄≤2岁、多部位骨质受累、有危险器官受累及初始治疗后疗效差是影响患者预后的重要因素。 Objective To explore the prognosis and the prognostic factors of patients with Langerhans cell histiocytosis. Methods The clinical and follow-up data of 111 cases with Langerhans cell histiocytosis ere collected and retrospectively analyzed. The state of recurrence was analyzed, and factors impacting on event-free survival(EFS) and overall survival(OS) were analyzed by univariate analyses. Results The patients with multisystem involvement and multiple bone involvement had a higher recurrence rate(P〈0.05). The univariate analyses indicated that the patients with the age of onset less than 2 years old, multiple bone involvement, multisystem involvement, risk organ involvement and a poor response to initial treatment had a lower EFS rate and OS rate, and the patients who had received chemotherapy had a higher EFS rate and OS rate. Conclusion The age of onset less than 2 years old, multiple bone involvement, risk organ involvement and responses to initial treatment are important prognostic factors.
出处 《中国实用内科杂志》 CAS CSCD 北大核心 2015年第12期1022-1026,共5页 Chinese Journal of Practical Internal Medicine
基金 国家自然科学基金(81370661)
关键词 组织细胞增多症 朗格汉斯细胞 复发 无事件生存期 总生存期 histiocytosis Langerhans-cell recurrence event-free survival overall survival
  • 相关文献

参考文献15

  • 1吴升华.郎格罕细胞组织细胞增生症评估与治疗指南介绍[J].中华儿科杂志,2012,50(2):155-158. 被引量:68
  • 2Hoover KB, Rosenthal DI, Mankin H, et al. Langerhans cell histiocytosis[J]. Skeletal Radiol, 2007, 36: 95-104. 被引量:1
  • 3树叶,曾迎红,周斌,陈卫坚,汤建萍.朗格汉斯细胞组织细胞增多症126例临床分析[J].中华皮肤科杂志,2013,46(4):273-275. 被引量:6
  • 4Baumgartner I, Hochstetter A, Baumert B, et al. Langerhans'cell histiocytosis in adults[J]. Med Pediatr Oncol, 1997, 28: 9-14. 被引量:1
  • 5Maia RC, Rezende LM, Robaina M, et al. Langerhans cell histiocytosis: Differences and similarities in long-term outcome of paediatric and adult patients at a single institutional centre[J]. Hematology3 2014, 3: 29-38. 被引量:1
  • 6Ronceray L, Potschger U, Janka G, et aL Pulmonary involvement in pediatric-onset multisystem Langerhans cell histiocytosis: effect on course and outcome[J].J Pediatr, 2012, 16: 129-33. e1-3. 被引量:1
  • 7Vassallo R, Ryu JH, Schroeder DR, et al. Clinical outcomes of pulmonary Langerhans'cell histiocytosis in adults[J]. N EnglJ Med, 2002, 346: 484-490. 被引量:1
  • 8Jubran P.F, Marachelian A, Dorey F, et al. Predictors of outcome in children with Langerhans cell histiocytosis[J]. Pediatr Blood Cancer, 2005, 45: 37-42. 被引量:1
  • 9Kilpatrick SE, Wenger DE, Gilchrist GS, et al. Langerhans' cell histiocytosis (histiocytosis X) of bone. A clinicopathologic analysis of 263 pediatric and adult cases[J]. Cancer, 1995, 76: 2741-2784. 被引量:1
  • 10The French Langerhans cell histiocytosis Study Group. A multiple retrospective survy of langerhans cell histiocytosis: 348 cases observed between 1983 and 1993[J]. Archives of Disease in Childhood, 1996, 75: 17-24. 被引量:1

二级参考文献35

  • 1王宏胜,李军,马伴吟,高怡瑾,陆凤娟,钱晓文.改良DAL-HX83/90方案治疗儿童郎格罕细胞组织细胞增生症24例疗效观察[J].中国小儿血液与肿瘤杂志,2007,12(2):60-63. 被引量:12
  • 2Histiocyte Society. Langerhans cell histiocytosis evaluation and treatment guideline. April,2009. Availabele from : http ://www. heamatologie-amc, nl/odijk/bijlagen. 被引量:1
  • 3Minkov M. Multisystem Langerhans cell histiocytosis in children: current treatment and future directions. Paediatr Drugs, 2011,13 : 75 -86. 被引量:1
  • 4Gadner I-I, Grois N, Arico M, et al. A randomized trial of treatment for multisystem Langerhans' cell histioeytosis. J Pediatr, 2001, 138:728-734. 被引量:1
  • 5treatment ot multisystem Langerhans cell histiocytosis : important prognostic indicator. Med Pediatr Oncol, 2002,39:581- 585. 被引量:1
  • 6Bernard F, Thomas C, Bertrand Y,et al. Multi-centre pilot study of 2-chlorodeoxyadenosine and cytosine arabinoside corobined chemotherapy in refractory Langerhans cell histiocytosis with haematological dysfunction. Eur J Cancer, 2005,41:2682-2689. 被引量:1
  • 7Steiner M, Matthes-Martin S, Attarbaschi A, et al. Improved outcome of treatment-resistant high-risk Langerhans cell histiocytosis after allogeneic stem cell transplantation with reduced- intensity conditioning. Bone Marrow Transplant, 2005,36: 215- 225. 被引量:1
  • 8Egeler RM, de Kraker J, Vo6te PA. Cytosine-arabinoside, vincristine, and prednisolone in the treatment of children with disseminated Langerhans cell histiocytosis with organ dysfunction: experience at a single institution. Med Pediatr Oncol, 1993,21: 265-270. 被引量:1
  • 9Stine KC, Saylors RL, Williams LL, et al. 2-Chlorodeoxyadenosine (2-CDA) for the treatment of refractory or recurrent Langerhans cell histiocytosis (LCH) in pediatric patients. Med Pediatr Oncol, 1997,29: 288-292. 被引量:1
  • 10Stine KC, Saylors RL, Saccente S, et al. Efficacy of continuous infusion 2-CDA (cladribine) in pediatric patients with Langerhans cell histiocytosis. Pediatr Blood Cancer, 2004,43:81-84. 被引量:1

共引文献75

同被引文献10

引证文献2

二级引证文献2

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部